Privia Health Group awarded director Ernest Opella Finley 6,350 shares at $0 per share on September 1, 2026. Finley then held 6,350 Privia Health shares, making the award a newly reported insider ownership position for investors tracking director stakes in PRVA.
Key Highlights
- The transaction was classified with code A, identifying it as an award.
- The shares carried a stated price of $0 per share.
- Ernest Opella Finley’s post-transaction ownership was 6,350 Privia Health shares.
Privia Health Group, Inc. (NASDAQ: PRVA) awarded director Ernest Opella Finley 6,350 shares on September 1, 2026. The shares were issued at $0 per share, and Finley’s resulting ownership totaled 6,350 shares.
Director Award Recorded at $0 Per Share
The stated consideration for the shares was $0 per share. The award covered 6,350 Privia Health shares. The transaction was also identified as a new insider position. The award date was September 1, 2026. Finley was the named recipient, and Privia Health Group, Inc. was the named company associated with the transaction. The reported share count remained 6,350 from the award through the resulting ownership position.
Finley’s Reported Ownership Position
The transaction therefore recorded both the director share award and Finley’s resulting holding in Privia Health Group, Inc.
FAQs
Q: How many Privia Health shares did Ernest Opella Finley receive?
A: Ernest Opella Finley received 6,350 Privia Health Group shares. The award was recorded at $0 per share on September 1, 2026.
Q: What was the impact of the Privia Health director share award?
A: The award gave director Ernest Opella Finley 6,350 shares of Privia Health Group, Inc. His resulting ownership position was also reported as 6,350 Privia Health Group shares.
Q: When did the Privia Health share award occur?
A: Privia Health Group recorded the director share award on September 1, 2026. Transaction code A identified the event as an award.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.